From Adjuvant to Metastatic in Melanoma: What Should You Know?

Access Course

 

From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

 

This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

 

The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

 

 

Approximate Time to Complete: 30 minutes

 

Credit Available: Dec. 24, 2018 - Dec. 24, 2019

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have greater competence related to selecting the most appropriate regimen for patients with melanoma
  • Have increased knowledge regarding the clinical trial data on the use of cancer immunotherapies in the management of melanoma
  • Have greater competence related to collaborating with other members of the interprofessional team to produce optimal outcomes in the identification and management of immune-related adverse events
Accreditation Council For Continuing Medical Education
AMA PRA Category 1 Credit(s)™: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Pharmacy Education
CEU: 0.50
(0.050 CEUs)